Data extraction and statistical errors: A quantitative critique of Gumley, Braehler, and Macbeth (2014).

Williams DR, Bürkner PC

The British journal of clinical psychology20 Feb 2017Cited by 1 (Europe PMC)

PMID28217976DOI10.1111/bjc.12130PepBankPUB-28217976

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In a re-analysis of meta-analyses of oxytocin in schizophrenia, the effect of oxytocin on positive symptoms was non-significant.
In plain wordsA re-check of earlier pooled trials found no significant effect of oxytocin on positive symptoms of schizophrenia.
Peptide
Oxytocin
Outcome
No significant changePositive symptoms of schizophrenia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
Whereas Gumley, Braehler, and Macbeth () reported oxytocin had significant effects on three of four outcomes, we show that all effects were non-significant.
1 context sentence(design, population, supporting numbers)
Summary · context
We reproduced the methods of Gumley, Braehler, and Macbeth (), including: outcomes (positive, negative, and total symptoms, as well as general psychopathology) and meta-analytic estimates for fixed and random effect models.
Report a problemFND-2821797601
02HumanSystematic reviewEfficacy outcome
In a re-analysis of meta-analyses of oxytocin in schizophrenia, the effect of oxytocin on negative symptoms was non-significant.
In plain wordsA re-check of earlier pooled trials found no significant effect of oxytocin on negative symptoms of schizophrenia.
Peptide
Oxytocin
Outcome
No significant changeNegative symptoms of schizophrenia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
Whereas Gumley, Braehler, and Macbeth () reported oxytocin had significant effects on three of four outcomes, we show that all effects were non-significant.
1 context sentence(design, population, supporting numbers)
Summary · context
We reproduced the methods of Gumley, Braehler, and Macbeth (), including: outcomes (positive, negative, and total symptoms, as well as general psychopathology) and meta-analytic estimates for fixed and random effect models.
Report a problemFND-2821797602
03HumanSystematic reviewEfficacy outcome
In a re-analysis of meta-analyses of oxytocin in schizophrenia, the effect of oxytocin on total symptoms was non-significant.
In plain wordsA re-check of earlier pooled trials found no significant effect of oxytocin on total symptoms of schizophrenia.
Peptide
Oxytocin
Outcome
No significant changeTotal symptoms of schizophrenia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
Whereas Gumley, Braehler, and Macbeth () reported oxytocin had significant effects on three of four outcomes, we show that all effects were non-significant.
1 context sentence(design, population, supporting numbers)
Summary · context
We reproduced the methods of Gumley, Braehler, and Macbeth (), including: outcomes (positive, negative, and total symptoms, as well as general psychopathology) and meta-analytic estimates for fixed and random effect models.
Report a problemFND-2821797603
04HumanSystematic reviewEfficacy outcome
In a re-analysis of meta-analyses of oxytocin in schizophrenia, the effect of oxytocin on general psychopathology was non-significant.
In plain wordsA re-check of earlier pooled trials found no significant effect of oxytocin on general psychopathology in schizophrenia.
Peptide
Oxytocin
Outcome
No significant changeGeneral psychopathology in schizophrenia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
Whereas Gumley, Braehler, and Macbeth () reported oxytocin had significant effects on three of four outcomes, we show that all effects were non-significant.
1 context sentence(design, population, supporting numbers)
Summary · context
We reproduced the methods of Gumley, Braehler, and Macbeth (), including: outcomes (positive, negative, and total symptoms, as well as general psychopathology) and meta-analytic estimates for fixed and random effect models.
Report a problemFND-2821797604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:49 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.